MedTrace Logo

Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome

NCT01775774 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2017-08-14

Study results available
· View outcomes & findings →

Summary

This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of hMSCs in patients with ARDS.

Conditions

  • Acute Respiratory Distress Syndrome

Interventions

BIOLOGICAL

Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells

Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Massachusetts General Hospital

    collaborator OTHER

  • Stanford University

    collaborator OTHER

  • University of Pittsburgh

    collaborator OTHER

  • University of Minnesota

    collaborator OTHER

  • Michael A. Matthay

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-02-28
Completion
2015-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01775774 on ClinicalTrials.gov